Exposure–response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma Academic Article uri icon

Overview

MeSH Major

  • Magnetic Resonance Imaging
  • Nuclear Magnetic Resonance, Biomolecular
  • Sarcoma

abstract

  • PFS/OS benefits occurred without a rate change in TEAEs across quartiles. Maximum benefit in OS was achieved in the upper three quartiles and a potential of early disease progression in the lower quartile of olaratumab serum exposure. These results prompted a loading dose strategy in the ongoing phase 3 STS trial.

publication date

  • January 2018

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1007/s00280-018-3723-4

PubMed ID

  • 30406840

Additional Document Info